AVDLのチャート
AVDLの企業情報
| symbol | AVDL |
|---|---|
| 会社名 | Avadel Pharmaceuticals PLC （フラメル・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms including Micropump LiquiTime Trigger Lock and Medusa. The Company offers its products in various categories including hospital including Bloxiverz Vazculep and Akovaz and pediatrics including Karbinal ER Cefaclor for Oral Suspension AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Cefaclor is indicated for the treatment of otitis media lower respiratory infections pharyngitis and tonsillitis urinary tract infections and skin and skin structure infections caused by susceptible organisms. フラメル・テクノロジ―ズはフランスのバイオ医薬品メ―カ―。ポリマ―ベ―スの薬剤送達技術を開発。マイクロポンプ技術は、放出制御、味覚マスキング及び生物学的利用強化の応用で小分子薬の経口投与を実現。メデュ―サ技術は、治療用たんぱく質、ペプチド、その他の大小分子薬の注入後の制御放出を行う。グラクソ・スミスクラインなどとの共同開発を行う。 Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. |
| 本社所在地 | Block 10-1 Blanchardstown Corporate Park Ballycoolin Dublin 15 IRL |
| 代表者氏名 | Michael S. Anderson マイケル・S・アンダーソン |
| 代表者役職名 | Chief Executive Officer Director 最高経営責任者（CEO） |
| 電話番号 | +353 1-485-1200 |
| 設立年月日 | 33086 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 180人 |
| url | www.avadel.com |
| nasdaq_url | https://www.nasdaq.com/symbol/avdl |
| adr_tso | 41900230 |
| EBITDA | EBITDA（百万ドル） -8.02700 |
| 終値（lastsale） | 4.46 |
| 時価総額（marketcap） | 186875025.8 |
| 時価総額 | 時価総額（百万ドル） 171.32290 |
| 売上高 | 売上高（百万ドル） 136.95000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 175.41290 |
| 当期純利益 | 当期純利益（百万ドル） -5.75300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Avadel Pharmaceuticals PLC (ADR) revenues decreased 37% to $62.5M. Net loss totaled $15.7M vs. income of $54.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Interest Expense increase from $526K to $4.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $1.33 to -$0.41. |
AVDLのテクニカル分析
AVDLのニュース
Analysts Set Expectations for Avadel Pharmaceuticals plc’s FY2023 Earnings (NASDAQ:AVDL) 2023/04/03 06:48:43 The AM Reporter
Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Rating) – Analysts at Lifesci Capital issued their FY2023 earnings estimates for Avadel Pharmaceuticals in a research note issued to investors on Thursday, March 30th. Lifesci Capital analyst A. Evertts expects that the company will earn ($0.64) per share for the year. The consensus estimate for Avadel Pharmaceuticals’ current […]
Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call Transcript 2023/04/01 01:25:09 Seeking Alpha
Avadel Pharmaceuticals plc (NASDAQ:NASDAQ:AVDL) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ETCompany ParticipantsAustin Murtagh – Stern Investor RelationsGreg Divis – Chief…
Avadel Pharmaceuticals GAAP EPS of -$0.44 misses by $0.17 (NASDAQ:AVDL) 2023/03/30 11:44:45 Seeking Alpha
Avadel Pharmaceuticals press release (AVDL): Q4 GAAP EPS of -$0.44 misses by $0.17.Cash, cash equivalents and marketable securities were $96.5 million as of December 31, 2022.The…
Earnings Scheduled For March 30, 2023 2023/03/30 11:24:25 Benzinga
Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.
Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results 2023/03/30 11:01:00 Finanz Nachrichten
• LUMRYZ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval …
Avadel requests final FDA approval for Lumyrz in narcolepsy 2023/03/02 13:15:22 Seeking Alpha
Avadel Pharmaceuticals (AVDL) has submitted an amendment to the FDA requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness ((EDS)) in…
Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ (sodium oxybate) extended-release oral suspension 2023/03/02 12:00:00 Wallstreet:Online
- Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it has submitted an amendment to the U.S. Food and Drug Administration (“FDA”) requesting final approval for
Avadel to seek full FDA nod for sleep therapy as Jazz loses patent appeal (NASDAQ:AVDL) 2023/02/24 19:41:27 Seeking Alpha
Avadel (AVDL) announced Friday its plans to seek final FDA approval for sleep disorder therapy Lumryz after Jazz Pharma (JAZZ) lost an appeal in a patent dispute. Read the full story here.
Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference 2023/02/08 13:00:00 GlobeNewswire
DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 1:00 p.m. ET.
Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates 2023/01/24 13:00:00 GlobeNewswire
- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose -
Avadel stock surges 13% as Jefferies upgrades on opportunity to dent Jazz''s market share 2022/11/30 16:32:58 Seeking Alpha
Avadel Pharmaceuticals (AVDL) stock rose ~13% on Wednesday after Jefferies Financial upgraded the shares to Buy from Hold on opportunity of taking market share from Jazz…
Investing in Avadel Pharmaceuticals plc (AVDL) might be a great opportunity, but the stock is a bit overvalued 2022/11/28 16:24:00 US Post News
Avadel Pharmaceuticals plc (NASDAQ:AVDL) marked $7.99 per share on Friday, up from a previous closing price of $7.81. While Avadel Pharmaceuticals plc has overperformed by 2.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVDL fell by -19.62%, with highs and lows ranging from $10.00 to […]
156K Reasons To Be Bullish On Avadel Pharmaceuticals Stock 2022/11/24 15:00:32 Benzinga
Eric J Ende , Director at Avadel Pharmaceuticals (NASDAQ: AVDL ), reported a large insider buy on November 23, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Ende purchased 20,000 shares of Avadel Pharmaceuticals. The total transaction amounted to $156,050. Avadel Pharmaceuticals shares are trading down 2.13% at $7.81 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to … Full story available on Benzinga.com
Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling 2022/11/21 19:32:48 Benzinga
Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc''s (NASDAQ: AVDL ) motion to delist the ‘963 Xyrem REMS patent. Needham says a favorable patent ruling clears a key hurdle for Lumryz, and Q3 FY23 is the most likely timeframe for full launch (vs. 4Q FY23 previously). The analyst has raised the price target to $9 from $8 with a Buy rating. Related:
Can you now get a good deal on Avadel Pharmaceuticals plc’s shares? 2022/11/21 14:08:00 US Post News
As of Friday, Avadel Pharmaceuticals plc’s (NASDAQ:AVDL) stock closed at $8.03, up from $7.16 the previous day. While Avadel Pharmaceuticals plc has overperformed by 12.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVDL fell by -17.22%, with highs and lows ranging from $10.18 to $1.05, […]